Responsible AI Is the Only Way Pharma Wins Trust From the FDA, EMA — and Patients
Pharma doesn’t lose approvals because of weak science. It loses them because regulators can’t trust the AI behind it.
December 24, 2025
Pharma doesn’t lose approvals because of weak science. It loses them because regulators can’t trust the AI behind it.
90% of pharma data is never used. But the 10% that is… is rewriting who wins and who loses in this industry.
Here’s the uncomfortable truth: validating an AI model once is like approving a drug that reformulates itself overnight. Model risk management is forcing pharma to confront this.
3 years ago, AI was a pilot project in pharma.
Today, it’s everywhere — and risk is scaling faster than governance.
The quiet winner holding it all together? Enterprise Risk Management.
Here’s the uncomfortable truth:
Pharma doesn’t trust most AI vendors.
And without bias controls, audit trails, and transparency, they never will.
Ethical AI is now the price of entry.
85% of pharma leaders want AI scale-up — but almost none have the talent required to make it safe.